You are here
New CML Data Post Signs on Route to Treatment-Free Remission
Increasing the proportion of patients with chronic myeloid leukemia (CML) who achieve a rapid decline in BCR-ABL1 transcript levels within the first year on therapy appears likely to boost the proportion who eventually achieve treatment-free remission, according to a critical review of available data. The evidence from CML stop-treatment trials, including new data presented at the 2016 annual meeting of the American Society of Hematology (ASH), indicate that indefinite disease control is dependent on not only suppressing BCR-ABL1 transcript levels below the threshold of detection, but also the speed at which that suppression is achieved.
"In CML, the focus has shifted from measuring cytogenetic response to monitoring transcript levels of BCR-ABL1, with particular attention to milestones of response over the first 12 months," said Susan Branford, PhD, head of the leukemia unit at the Center for Cancer Biology in Adelaide, Australia, speaking on the state of molecular monitoring of CML at the 2016 ASH meeting.